Elutia
Private Company
Funding information not available
Overview
Elutia is a commercial-stage medical device company developing and marketing innovative drug-eluting biomaterials to combat complications from surgical implants. Its platform technology fuses natural biologic matrices with controlled antibiotic release to create envelopes and matrices for device implantation and soft tissue reconstruction. The company's lead products, CanGaroo and SimpliDerm, target the electrophysiology, neuromodulation, and plastic surgery markets to improve patient outcomes and reduce healthcare costs. Founded in 2019 and led by industry veteran C. Randal Mills, Elutia aims to humanize medicine by ensuring patients can thrive without compromise post-surgery.
Technology Platform
Proprietary drug-eluting biomaterial platform that fuses natural, acellular biologic matrices with controlled-release drug delivery (primarily antibiotics) to create implantable envelopes and matrices designed to prevent infection, reduce fibrosis, promote healing, and ensure device stability.
Opportunities
Risk Factors
Competitive Landscape
Competes with large medical device companies (e.g., Medtronic, Abbott) that offer their own device envelopes and matrices, as well as established regenerative medicine companies providing acellular dermal matrices (e.g., Allergan, Integra). Differentiation is based on the proprietary combination of biomaterial and controlled drug elution to address fibrosis and infection simultaneously.